Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-013351
Filing Date
2022-08-11
Accepted
2022-08-11 17:25:13
Documents
56
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cycc-20220630x10q.htm   iXBRL 10-Q 1226814
2 EX-31.1 cycc-20220630xex31d1.htm EX-31.1 14688
3 EX-31.2 cycc-20220630xex31d2.htm EX-31.2 15230
4 EX-32.1 cycc-20220630xex32d1.htm EX-32.1 5091
5 EX-32.2 cycc-20220630xex32d2.htm EX-32.2 5435
  Complete submission text file 0001558370-22-013351.txt   4876207

Data Files

Seq Description Document Type Size
6 EX-101.SCH cycc-20220630.xsd EX-101.SCH 35711
7 EX-101.CAL cycc-20220630_cal.xml EX-101.CAL 35134
8 EX-101.DEF cycc-20220630_def.xml EX-101.DEF 174687
9 EX-101.LAB cycc-20220630_lab.xml EX-101.LAB 300312
10 EX-101.PRE cycc-20220630_pre.xml EX-101.PRE 265216
50 EXTRACTED XBRL INSTANCE DOCUMENT cycc-20220630x10q_htm.xml XML 682774
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-50626 | Film No.: 221157015
SIC: 2834 Pharmaceutical Preparations